NCT01480323View on ClinicalTrials.gov

A Phase II Study to Evaluate Safety and Efficacy of Combined Treatment With Ipilimumab and Intratumoral Interleukin-2

PHASE2CompletedINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

February 29, 2012

Primary Completion Date

September 30, 2014

Study Completion Date

June 30, 2015

Conditions
Malignant Melanoma
Interventions
DRUG

Interleukin-2

intratumoral injections of 9 MIU/day on days 1, 4, 8, 11, 15, 18, 22 and 25. The administered dose will be distributed between all injectable soft-tissue metastases

DRUG

Ipilimumab

IV infusion, 3 mg/kg, day 2, 23, 44, 65

Trial Locations (1)

72076

University Hospital Tübingen, Tübingen

All Listed Sponsors
lead

University Hospital Tuebingen

OTHER

NCT01480323 - A Phase II Study to Evaluate Safety and Efficacy of Combined Treatment With Ipilimumab and Intratumoral Interleukin-2 | Biotech Hunter | Biotech Hunter